---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-22-026356"
form_type: "8-K"
ticker: "VXRT"
cik: "0000072444"
company_name: "Vaxart, Inc."
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T04:43:32.930166+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Vaxart Q3 net loss $29.3M; cash $114.8M; clinical milestones set for 2023

## Summary
- Net loss $29.3M ($0.23 EPS) vs $17.6M ($0.14) Q3 2021; R&D spend rose 81% to $22.5M.
- Cash & securities $114.8M at Sep 30, down from $131.5M at Jun 30; ops used $14.6M.
- Phase II COVID-19 vaccine showed mucosal IgA and cross-reactivity to Omicron; UK challenge trial set for 2H 2023.
- Norovirus Phase Ib in elderly (55-80) showed dose-dependent IgA; Phase II challenge data expected Q1/Q2 2023.
- Added Ray Stapleton as CTO and Elaine Heron & Mark Watson to board in August 2022.

## SEC filing metadata
- accession: 0001437749-22-026356
- form_type: 8-K
- ticker: VXRT
- cik: 0000072444
- company_name: Vaxart, Inc.
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/72444/000143774922026356/0001437749-22-026356-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/72444/000143774922026356/vxrt20221014_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-22-026356
- JSON: https://secwatch.observer/filing/0001437749-22-026356.json
- Plain text: https://secwatch.observer/filing/0001437749-22-026356.txt

## Key facts
- Earnings Releases
  Vaxart, Inc. reported financial results for the quarter ended September 30, 2022.
  - Period: the quarter ended September 30, 2022
  - Result: reported results
  source text: On November 8, 2022, Vaxart, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/72444/000143774922026356/0001437749-22-026356-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.